Recent evidence for cross-talk between protein kinase B (PKB) and the Raf-1 and NF-κ κB signalling pathways has provided new hints to the complex roles that PKB may play in regulating gene transcription and also raised questions about where and when these targets are relevant. Recent years have witnessed an explosion of information describing the roles of protein kinase B (PKB), also known as c-Akt, in signal transduction. This has come about following the revelation that PKB is regulated by the important receptor-proximal lipid kinase phosphoinositide 3-kinase (PI 3-kinase), and the lipid phosphatases PTEN and SHIP. PKB may carry a significant burden of the roles that PI 3-kinase plays in cell growth, differentiation, shape, and survival. In recent months evidence has been published indicating that two separate and important pathways, one involving the transcription factor NF-κB and the other the Ras-Raf-MAP kinase pathway, are modulated by PKB. This cross-talk between PI 3-kinase-PKB and two seemingly parallel pathways opens up many new possibilities for how receptor activation may control cellular function. It should also be noted that the sometimes contradictory findings among these studies suggests that we should also move with caution in defining direct targets of PKB.
The guanine-nucleotide-binding protein Ras has long been recognised as an important proto-oncogene product, and its proliferative signal is believed to be transmitted in part via the serine/threonine kinase Raf-1. Raf-1 controls the activation of the MAP kinase/Erk kinase (MEK) and its downstream target Erk. This linear MAP kinase pathway facilitates the communication of membrane receptors with transcription factor targets of Erk, thereby altering the protein activity state of any given cell during its growth or differentiation process. It has also become clear that the strength and duration of Erk activation are important determinants that govern the biological response to a particular input.
One means by which two pathways co-activated by the same or different receptors may subtly control divergent targets is through cross-talk. Following this theme, a negative role for PKB in Raf-1-Erk signalling has recently been reported by several groups. Raf-1 activation is complex, and involves multiple levels of membrane recruitment, phosphorylation and binding with 14-3-3 molecules. Zimmermann et al. [1] and Rommel et al. [2] have now shown that at least some modes of regulation of Raf-1 involve an input from PKB, although they have suggested somewhat different mechanisms.
In the study reported by Zimmermann et al. [1] , PKB was shown to directly phosphorylate Raf-1 on residue serine 259, an inactivating site, leading to reduced activity. The site surrounding serine 259 falls into the much-hyped 'RXRXXS' motif, which is found in other putative PKB targets. This motif is also a classical 14-3-3 binding region, and binding of 14-3-3 proteins to this domain is associated with reduced MEK phosphorylation. Zimmermann et al. [1] further provided evidence that PKB can bind Raf-1 in several cell types.
This model would predict a series of temporal events following receptor activation. First, tyrosine phosphorylation at the plasma membrane would lead to activation of both PI 3-kinase activation and Ras (the latter via recruitment of the adaptor protein Grb2 and the Ras guaninenucleotide exchange factor Sos). Both Raf-1 and PKB translocate from the cytoplasm to the plasma membrane and become targets of other upstream activating kinases, including phosphoinositide-dependent kinase 1 (PDK1) and protein kinase C (PKC) isoforms. Raf-1 activity would then be expected to decline, in part because of phosphorylation of serine 259 by PKB and consequent association with 14-3-3 proteins. During tonic low levels of stimulation, PKB might then place a ceiling on the overall level of Raf-1 activity, a restriction abolished by PI 3-kinase (and hence PKB) inhibitors. Most of the experiments reported by Zimmermann et al. [1] involved measurements of Raf-1 activity following a single time point of stimulation, and it will be of interest to explore the effects of PKB on Raf-1 over time. Erk often undergoes biphasic activation, and it is tempting to speculate that this behaviour is a consequence of a transient PKB 'throttle'.
In the work of Rommel et al. [2] , the contributions of the PKB and Raf-1 pathways were assessed during myotube differentiation. In this system, PKB was shown to reduce Raf-1 phosphorylation on serine 338, an activating site, in post-differentiation myotubes. Either enforced activation of PKB or treatment with a MEK inhibitor promoted myotube formation, while enforced Raf-1 activity blocked differentiation in the precursor myoblast stage. The picture that emerges is that a balance in signal strength between PKB and Raf-1 decides for or against differentiation. Of note, the effects of PKB on Raf-1 were found to be differentiation-state-specific. Accordingly, an association of Raf-1 with PKB was observed only in post-differentiation myotubes. This implies that accessory molecules, such as 14-3-3, or subcellular localization are important for PKB-Raf-1 interaction. Downregulation of serine 338 phosphorylation would suggest activation of, or exposure to, a phosphatase, which may be part of the PKB-Raf-1 complex. Rommel et al. [2] did not examine phosphorylation of residue serine 259. The two sets of results might be reconciled if inhibition of Raf-1 activity through serine 259 phosphorylation leads to decreased serine 338 phosphorylation. Thus, the overall effects of PKB on Raf-1 may involve multiple steps of phosphorylation and dephosphorylation.
These studies have uncovered an unexpected degree of interaction between two parallel, receptor-proximal pathways. The capacity of PKB to dampen the extent and duration of Erk activation could provide an important element of control for gene transcription and help explain how two simultaneously activated, parallel pathways interact to promote a cell through a differentiation or proliferation process. However, several caveats should be born in mind when assessing the directness of the effects. First, the use of transiently expressed, constitutively-active or dominant-negative PKB constructs may force interactions that rarely occur naturally. Further, some of the effects of constitutively-active PKB on Raf-1 could be explained through secondary activation of other kinases or phosphatases. Thus, while the interactions between PKB and Raf-1 look promising, whether Raf-1 really is a direct target of PKB remains to be firmly established.
Zimmermann et al. [1] used transformed cell lines in their work, and it is possible that a constant level of PKB-mediated Raf-1 inhibition is required for sustained proliferation of such cells. This may explain why PKB was found to be constitutively associated with Raf-1 in this model system, but not in the differentiating myoblasts studied by Rommel et al. [2] . Another complexity is the seemingly contradictory findings by others over the past few years that inhibition of PI 3-kinase by pharmacological inhibitors or by expression of dominant-negative forms of PI 3-kinase can actually reduce Erk activity [3, 4] . Thus, PI 3-kinase may play several distinct roles in the regulation of the Erk pathway, both positive and negative, depending on the input signal and strength, the cell type and the differentiation state (Figure 1) . The two new studies [1, 2] highlight the differences that can occur between cell-type systems and further dispel the myth that signal transduction pathways are generic or 'hardwired'.
In the course of investigating a completely different signalling arm, three laboratories [5] [6] [7] have uncovered a link between NF-κB activation and the PI 3-kinase-PKB pathway (Figure 2 ). Unlike the antagonism mediated by PKB on Raf-1 activation, PKB was found to increase NF-κB activation. Weiss and colleagues [5] first demonstrated in T-cell lines that activated PKB synergistically elevated NF-κB-mediated gene expression following stimulation with phorbol esters [5] . Further mechanistic details were later provided by two other groups [6, 7] , who showed that agonists that induce NF-κB activation, such as tumour necrosis factor α (TNF-α) or platelet-derived growth factor (PDGF), can act in part through PKB activation to activate IKK, the upstream kinase that phosphorylates the inhibitory component I-κB. Phosphorylation of I-κB by IKK leads to its ubiquitinylation and degradation, freeing the cytosolic NF-κB to translocate to the nucleus where it can modulate gene expression. But the new studies show that this model of activation is complex, and, as in the case of Raf modulation described above, there are some conspicuous differences between the inferred mechanism in each study that may be attributable to cell type or experimental approach.
In one study [6] , inhibitors of PI 3-kinase or a dominantnegative form of PKB were found to ablate TNF-α-induced Depending on the cellular context, Raf-1 and PKB may induce opposing cell responses, such as differentiation versus proliferation, or apoptosis versus survival. The balance between these decisions is controlled by the strength and duration of Raf-1 and PKB activation. Many of the positive inputs into Raf-1 are shared with PKB, resulting in simultaneous activation. PKB may tip the scale in its favour when it is turned on by directly suppressing Raf-1.
activation of NF-κB in 293 cells. Furthermore, a constitutively-active form of PKB stimulated NF-κB to a similar degree as TNF-α, showing that active PKB alone is sufficient to drive NF-κB activation in these cells. In contrast, in experiments with human fibroblasts [7] , inhibition of PI 3-kinase had no effect on TNF-α-induced NF-κB activation, indicating that PKB is dispensable for NF-κB activation in these cells. Observations supporting this view were recently made in dendritic cells and osteoclasts, where the TNF-α-related protein TRANCE was shown to activate both PKB and NF-κB through independent pathways [8] . Another significant difference between these studies involved the association of PKB with its suspected target, IKK. While the association appears to be constitutive in 293 cells, it was transient in primary fibroblasts. And if this scenario was not already complex enough, a separate study has suggested that PKB directly phosphorylates and regulates NF-κB, independent of effects on I-κB stability [9] . Together, these findings indicate that PKB contributes multiple inputs leading to NF-κB activation, some of which are dependent on the cellular system.
Of the many cellular processes governed by PI 3-kinase, one major outcome of PKB activation is protection from apoptosis [10] . With the expanding list of substrates assigned to PKB, the opportunities that present themselves for survival signalling are also growing, and include human caspase-9, Bad and Forkhead transcription factors [11] . Raf-1 and NF-κB can now be included in this list. Expression of an oncogenic form of Ras can induce apoptosis, suggesting that inappropriate activation of the Raf-MAP kinase pathway, particularly in the absence of PI 3-kinase/PKB signalling, triggers an apoptotic signal. Thus, PKB may provide some protection from apoptosis by suppressing excessive Raf-1 signalling (too much of a good thing...). The pro-survival effects of activated NF-κB are well documented [12] , and so the relevance of an input from PKB is obvious.
Other pathways besides NF-κB and Raf-1 are likely to contribute to the pro-survival function of PKB. Members of the Forkhead family of transcription factors are among the most plausible targets -in this case, the evidence from experiments with mammalian cell lines is supported by earlier genetic experiments performed in Caenorhabditis elegans [13, 14] . But the relevance of some of the other suggested targets has been questioned -in the case of caspase-9, for example, the 'RXRXXS' motif phosphorylated by PKB in the human enzyme is absent in the mouse homolog [15] .
The relationship between PKB and Bad is similarly complicated. Early evidence correlated Bad phosphorylation, which reduces its pro-apoptotic activity, with expression of activated PKB or decreased Bad phosphorylation following treatment with PI 3-kinase inhibitors. Furthermore, the Bad phosphorylation level was found to be elevated in cell lines deficient for PTEN lipid phosphatase activity [16] . PTEN is a negative regulator of PKB, and so the effects observed were attributed to the elevated PKB activity in these cells. But, as in the case of Raf-1, it would appear that PKB activation does not always lead to Bad phosphorylation [17] .
There is emerging evidence that the Ras-MAP kinase pathway may also play a significant role in increasing Bad phosphorylation [17, 18] . As discussed above, given that there may be cross-talk between the PI 3-kinase-PKB pathway and the Ras-MAP kinase pathway at various levels, with both positive and negative interactions, some Dispatch R193
Figure 2
Until recent years, three separate pathways were believed to operate downstream of growth factor receptors to regulate gene transcription, survival and differentiation (left panel). Now these pathways can be unified, providing interdependence and coordination of signalling consequences (right panel).
of the effects on Bad attributed to PI 3-kinase and PKB may in fact be due to changes in MAP kinase activity (Figure 2 ). This view is supported by the observation that expression of PTEN decreases Bad phosphorylation at sites targeted in vivo by the Ras-MAP kinase pathway as well as PKB [16, 19] .
These examples highlight the difficulties associated with studying intertwined pathways initially thought to operate independently, and, in particular, with identifying direct substrates of PKB (or any protein kinase for that matter). A common factor in all of these studies is the use of transiently expressed, constitutively-active PKB. This genetic tool has been useful in sorting out the various inputs that PKB makes in the global cellular network, while avoiding the lack of specificity associated with pharmacological inhibitors of PI 3-kinase. But it also has its pitfalls: a lack of similarity to the time-course of PKB activation that naturally follows receptor activation; a disproportionate level of PKB protein compared to endogenous binding partners and substrates; and the possibility of complication by autocrine or paracrine signalling events, especially as PKB affects gene expression by a host of potential targets, such as the Forkhead and NF-κB transcription factors. Studies that use rapid, inducible activation strategies and selective small-molecule inhibitors of PKB will be crucial in more closely approximating the temporal activation of PKB that naturally follows cell stimulation by a growth factor, and should help in assessing which PKB targets are truly physiologically relevant and under what circumstances.
